V
Venkata Satish Kumar Mattaparthi
Researcher at Tezpur University
Publications - 38
Citations - 188
Venkata Satish Kumar Mattaparthi is an academic researcher from Tezpur University. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 6, co-authored 29 publications receiving 122 citations. Previous affiliations of Venkata Satish Kumar Mattaparthi include Indian Institute of Technology Guwahati.
Papers
More filters
Journal ArticleDOI
Daboxin P, a Major Phospholipase A2 Enzyme from the Indian Daboia russelii russelii Venom Targets Factor X and Factor Xa for Its Anticoagulant Activity
Maitreyee Sharma,Janaki Krishnamurthy Iyer,Norrapat Shih,Munmi Majumder,Venkata Satish Kumar Mattaparthi,Rupak Mukhopadhyay,Robin Doley +6 more
TL;DR: This is the first report of a phospholipase A2 enzyme from Indian viper venom which targets both factor X and factor Xa for its anticoagulant activity.
Journal ArticleDOI
Bis- and mixed-ligand copper(II) complexes of nalidixic acid the antibacterial drug: Mode of nalidixate coordination determines DNA binding and cleavage and cytotoxicity
Mitu Sharma,Mani Ganeshpandian,Airy Sanjeev,Ajaykamal Tamilarasan,Venkata Satish Kumar Mattaparthi,Nashreen S. Islam,Mallayan Palaniandavar +6 more
TL;DR: DNA docking studies reveal that 2 bound to DNA undergoes interesting coordinative distortions more than 1, causing more significant changes in DNA host, and displays oxidative DNA cleavage more prominent than [Cu(en)2]2+, by generating OH radicals, and shows poor cytotoxicity towards A549 lung cancer cell lines.
Journal ArticleDOI
Computational investigation on the effect of Oleuropein aglycone on the α-synuclein aggregation.
TL;DR: The findings in this study substantiate the effect of OleA on the structure and stabilization of α-synuclein monomer that subsequently favors the growth of stable and nontoxic aggregates.
Journal ArticleDOI
Chemical system biology approach to identify multi-targeting FDA inhibitors for treating COVID-19 and associated health complications
Biswajit Naik,Venkata Satish Kumar Mattaparthi,Nidhi Gupta,Rupal Ojha,Pundarikaksha Das,Satyendra Singh,Vijay Kumar Prajapati,Dhaneswar Prusty +7 more
TL;DR: Sarma et al. as mentioned in this paper carried out molecular docking studies of compounds from the FDA approved drug library and passed phase-1 drug libraries with ten therapeutic targets of COVID-19 and showed that known drugs, including nine anti-inflammatory compounds, four antibiotics, six antidiabetic compounds, and one cardioprotective compound, could effectively inhibit multiple therapeutic targets.
Journal ArticleDOI
1α, 25-dihydroxy Vitamin D3 containing fractions of Catharanthus roseus leaf aqueous extract inhibit preadipocyte differentiation and induce lipolysis in 3T3-L1 cells.
Anuj Kumar Borah,Archana Singh,Rafika Yasmin,Robin Doley,Venkata Satish Kumar Mattaparthi,Sougata Saha +5 more
TL;DR: 1α, 25-dihydroxy Vitamin D3 containing CRACE can be developed into an effective anti-obesity formulation that decreases adipogenesis and increases lipid catabolism.